Spruce Biosciences/$SPRB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Spruce Biosciences
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Ticker
$SPRB
Sector
Primary listing
Employees
14
Headquarters
Website
SPRB Metrics
BasicAdvanced
$134m
-
-$38.62
3.20
-
Price and volume
Market cap
$134m
Beta
3.2
52-week high
$240.00
52-week low
$7.26
Average daily volume
51k
Financial strength
Current ratio
4.67
Quick ratio
4.589
Long term debt to equity
16.728
Total debt to equity
20.555
Interest coverage (TTM)
-35.86%
Profitability
EBITDA (TTM)
-25.841
Management effectiveness
Return on assets (TTM)
-37.16%
Return on equity (TTM)
-148.85%
Valuation
Price to book
1.93
Price to tangible book (TTM)
1.93
Price to free cash flow (TTM)
-1.6
Free cash flow yield (TTM)
-62.48%
Free cash flow per share (TTM)
-30.467
Growth
Earnings per share change (TTM)
-61.02%
3-year earnings per share growth (CAGR)
-34.62%
SPRB News
AllArticlesVideos
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
Business Wire·3 days ago
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
Business Wire·1 week ago
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs